941TiPENGOT-OV16/NOVA: A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH PARP-INHIBITOR NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER.

Sorry, there's nothing here.

Cite this paper

@article{Mirza2014941TiPENGOTOV16NOVAAP, title={941TiPENGOT-OV16/NOVA: A PHASE 3 RANDOMIZED DOUBLE-BLIND TRIAL OF MAINTENANCE WITH PARP-INHIBITOR NIRAPARIB VERSUS PLACEBO IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER.}, author={Mansoor Mirza and Bradley J. Monk and Jonathan A. Ledermann and Amit M. Oza and Jose Mar{\'i}a del Campo del Campo and Jonathan S. Berek and Sven Mahner and Robert Michael Wenham and Ignace Vergote and Michel Fabbro and Christian Marth and Anne D\orum and Domenica Lorusso and Dionyssios Katsaros and Ilan Bruchim and Susanne Malander and J\orn Herrstedt and Sudanshu Agarwal and Robert Martell and Ursula A. Matulonis}, journal={Annals of oncology : official journal of the European Society for Medical Oncology}, year={2014}, volume={25 suppl_4}, pages={iv325} }